You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Fluphenazine (oral) versus placebo for schizophrenia
|
|---|---|
| Published in |
Cochrane database of systematic reviews, July 2013
|
| DOI | 10.1002/14651858.cd006352.pub2 |
| Pubmed ID | |
| Authors |
Hosam E Matar, Muhammad Qutayba Almerie, Stephanie Sampson |
| Abstract |
Fluphenazine is one of the first drugs to be classed as an 'antipsychotic' and has been widely available for five decades. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 22% |
| India | 1 | 11% |
| Colombia | 1 | 11% |
| Unknown | 5 | 56% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 67% |
| Practitioners (doctors, other healthcare professionals) | 2 | 22% |
| Scientists | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 56 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 56 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 11 | 20% |
| Researcher | 7 | 13% |
| Student > Bachelor | 6 | 11% |
| Student > Ph. D. Student | 6 | 11% |
| Student > Doctoral Student | 5 | 9% |
| Other | 6 | 11% |
| Unknown | 15 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 30% |
| Psychology | 9 | 16% |
| Social Sciences | 4 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
| Other | 6 | 11% |
| Unknown | 16 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 May 2017.
All research outputs
#2,771,830
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#5,402
of 11,499 outputs
Outputs of similar age
#21,664
of 192,084 outputs
Outputs of similar age from Cochrane database of systematic reviews
#132
of 297 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 192,084 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 297 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.